Market Place
Sourcing Support
FDA Updates Camzyos Label to Reduce Monitoring Requirements
17 Apr 2025 //
BUSINESSWIRE
OpenFold AI Research Consortium Welcomes New Members
15 Apr 2025 //
BUSINESSWIRE
BMS` heart disease drug fails to meet main goals in study
15 Apr 2025 //
PRESS RELEASE
BMS`s Biologic Yervoy Receives Suppl Approval in US
11 Apr 2025 //
FDA
BMS`s Biologic Opdivo Receives Suppl Approval in US
11 Apr 2025 //
FDA
FDA approves Opdivo and Yervoy for Hepatocellular Carcinoma
11 Apr 2025 //
BUSINESSWIRE
Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly
09 Apr 2025 //
REUTER
FDA approves Opdivo & Yervoy for untreated colorectal cancer
08 Apr 2025 //
BUSINESSWIRE
Halozyme: BMS Gets CHMP Nod For Subcutaneous Opdivo
31 Mar 2025 //
PR NEWSWIRE
Bristol Myers Gets Positive CHMP Opinion for Opdivo Subcutaneous
28 Mar 2025 //
BUSINESSWIRE
Bristol Myers Squibb Gets CHMP Nod for Opdivo in Lung Cancer
28 Mar 2025 //
BUSINESSWIRE
BMS Appoints Osama Braiwish As GM For Saudi, Gulf Region
20 Mar 2025 //
PR NEWSWIRE
Bristol Myers Squibb gets EU approval to expand Breyanzi
14 Mar 2025 //
BUSINESSWIRE
Bristol Myers Squibb to Report Q1 2025 Results on April 24
13 Mar 2025 //
BUSINESSWIRE
2seventy bio Enters into Agreement to be Acquired by BMS
11 Mar 2025 //
BUSINESSWIRE
BMS Presents Ph3 Data Showing Sotyktu Superiority in Psoriatic Arthritis
10 Mar 2025 //
BUSINESSWIRE
BMS` Sotyktu Superior In Ph3 POETYK PsA-2 Psoriatic Study
08 Mar 2025 //
BUSINESSWIRE
BMS Gets EU Nod For Opdivo+Yervoy In Advanced Liver Cancer
07 Mar 2025 //
BUSINESSWIRE
Evotec Advances Neuroscience Alliance with Bristol Myers Squibb
04 Mar 2025 //
CONTRACTPHARMA
BMS telegraphs 223 more job cuts in its home state of NJ
04 Mar 2025 //
FIERCE PHARMA
Bristol Myers Squibb Announces Dividend
03 Mar 2025 //
BUSINESSWIRE
Bristol Myers to Participate in Upcoming Investor Conferences
25 Feb 2025 //
BUSINESSWIRE
FDA Accepts BMS’ sBLA For Opdivo + Yervoy In MSI-High, Cancer
24 Feb 2025 //
BUSINESSWIRE
BioArctic`s global license agreement with Bristol Myers Squibb
20 Feb 2025 //
PR NEWSWIRE
BMS`s Opdivo scores overall survival triumph in NSCLC trial
20 Feb 2025 //
FIERCE PHARMA
BMS’ Opdivo Combo Shows OS Benefit In Resectable NSCLC
19 Feb 2025 //
BUSINESSWIRE
Rancho BioSciences, BMS Extend Single-Cell Consortium Partnership
18 Feb 2025 //
ACCESSWIRE
Five-Year Sotyktu Data Shows Safety In Plaque Psoriasis
18 Feb 2025 //
BUSINESSWIRE
BMS Updates On Ph 3 RELATIVITY-098 Trial Results
15 Feb 2025 //
INDPHARMAPOST
BMS’ Opdualag flunks trial as adjuvant for resected melanoma
14 Feb 2025 //
FIERCE PHARMA
BMS Provides Update On Ph 3 RELATIVITY-098 Trial
13 Feb 2025 //
BUSINESSWIRE
BMS Announces Results for Breyanzi in Marginal Zone Lymphoma
10 Feb 2025 //
BUSINESSWIRE
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success
07 Feb 2025 //
BIOSPACE
Bristol Myers forecasts steeper drop in 2025 revenue, shares fall
06 Feb 2025 //
REUTERS
Bristol MyersReports Q4 and Full-Year Financial Results for 2024
06 Feb 2025 //
BUSINESSWIRE
BMS Gets Positive CHMP Opinion For Breyanzi In Follicular Lymphoma
31 Jan 2025 //
BUSINESSWIRE
BMS Gets Positive CHMP Opinion For Opdivo-Yervoy In Liver Cancer
31 Jan 2025 //
BUSINESSWIRE
BMS`s CheckMate -8HW Opdivo+Yervoy Vs. Opdivo Monotherapy Results
24 Jan 2025 //
BUSINESSWIRE
ArsenalBio, BMS Achieve Milestone For AB-4000 T Cell Program
13 Jan 2025 //
GLOBENEWSWIRE
BMS Named to Dow Jones Sustainability Index North America
10 Jan 2025 //
ACCESSWIRE
BMS extends Medidata partnership to adopt new digital tools
08 Jan 2025 //
FIERCE BIOTECH
BMS to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
03 Jan 2025 //
BUSINESSWIRE
FDA approves BMS` subcutaneous Opdivo with some limitations
02 Jan 2025 //
FIERCE PHARMA
BMS secures subcutaneous Opdivo approval
28 Dec 2024 //
FDA
BMS`s Biologic Opdivo Qvantig Receives Approval in US
27 Dec 2024 //
FDA
Sotyktu has excelled in 2 psoriatic arthritis trials, BMS says
26 Dec 2024 //
FIERCE PHARMA
Bristol Myers Squibb Receives EC Approval for Opdivo + Yervoy in CRC
23 Dec 2024 //
BUSINESSWIRE
BioArctic Signs Global License with Bristol Myers Squibb
19 Dec 2024 //
PR NEWSWIRE
Bristol Myers Squibb to Report Q4 2024 Results on Feb 6, 2025
19 Dec 2024 //
BUSINESSWIRE
BMS pays Leqembi originator $100M for Alzheimer`s prospects
19 Dec 2024 //
FIERCE BIOTECH
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space
19 Dec 2024 //
FIERCE PHARMA
BMS pays Leqembi originator $100M for Alzheimer’s prospects
19 Dec 2024 //
FIERCE BIOTECH
Fangzhou Partners with Bristol Myers Squibb on Internet Healthcare
18 Dec 2024 //
PR NEWSWIRE
Insitro Receives $25M in Milestone Payments from Bristol Myers Squibb
18 Dec 2024 //
BUSINESSWIRE
Bristol Myers culls cell therapy deals with 2 biotechs
17 Dec 2024 //
FIERCE BIOTECH
Bristol Myers Squibb Announces Dividend Increase
11 Dec 2024 //
BUSINESSWIRE
Acadia nabs Lexicon alum as new commercial lead
11 Dec 2024 //
FIERCE PHARMA
Bristol Myers Squibb Highlights Cell Therapy Portfolio at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
BMS taps AI Proteins in discovery collaboration worth up to $400M
04 Dec 2024 //
FIERCE BIOTECH
Bristol Myers Sues Federal Government Over 340B Drug Pricing
27 Nov 2024 //
ENDPTS
